First report of molecular detection of fluoroquinolone resistance-associated gyrA mutations in multidrug-resistant clinical Mycobacterium tuberculosis isolates in Kuwait
Open Access
- 14 April 2011
- journal article
- Published by Springer Nature in BMC Research Notes
- Vol. 4 (1) , 123
Abstract
Nearly 5% of all Mycobacterium tuberculosis strains worldwide are resistant at least to rifampicin and isoniazid (multidrug-resistant tuberculosis, MDR-TB). Inclusion of a fluoroquinolone and an injectable agent (kanamycin, amikacin or capreomycin) in multidrug therapy is crucial for proper treatment of MDR-TB. The incidence of MDR-TB in Kuwait is ~1%. MDR-TB strains additionally resistant to fluoroquinolones and injectable agents are defined as extensively drug-resistant (XDR-TB) strains and have been detected in >55 countries. Infections with XDR-TB strains have very poor prognosis. This study detected the occurrence of gyrA mutations associated with fluoroquinolone resistance among MDR-TB strains in Kuwait.Keywords
This publication has 35 references indexed in Scilit:
- New approaches in the diagnosis and treatment of latent tuberculosis infectionRespiratory Research, 2010
- High Level of Cross-Resistance between Kanamycin, Amikacin, and Capreomycin among Mycobacterium tuberculosis Isolates from Georgia and a Close Relation with Mutations in the rrs GeneAntimicrobial Agents and Chemotherapy, 2009
- Feasibility of the GenoType MTBDR sl Assay for Fluoroquinolone, Amikacin-Capreomycin, and Ethambutol Resistance Testing of Mycobacterium tuberculosis Strains and Clinical SpecimensJournal of Clinical Microbiology, 2009
- Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysisThe Lancet Infectious Diseases, 2009
- Predictors of poor treatment outcome in multi- and extensively drug-resistant pulmonary TBEuropean Respiratory Journal, 2009
- Minor contribution of mutations at iniA codon 501 and embC-embA intergenic region in ethambutol-resistant clinical Mycobacterium tuberculosis isolates in KuwaitAnnals of Clinical Microbiology and Antimicrobials, 2009
- Comprehensive Treatment of Extensively Drug-Resistant TuberculosisNew England Journal of Medicine, 2008
- Molecular Characterization of Ofloxacin-ResistantMycobacterium tuberculosisStrains from RussiaAntimicrobial Agents and Chemotherapy, 2008
- Randomized Trials to Optimize Treatment of Multidrug-Resistant TuberculosisPLOS Medicine, 2007
- Emergence of Ofloxacin Resistance in Mycobacterium tuberculosis Clinical Isolates from China as Determined by gyrA Mutation Analysis Using Denaturing High-Pressure Liquid Chromatography and DNA SequencingJournal of Clinical Microbiology, 2006